PUBLICATIONS

2016

In silico fragment-based hit identification for efficient discovery of new cosmetic ingredient

RICT 2016

Smart chemical libraries from Prestwick Chemical: powerful tools for high-quality hit discovery

Med. Chem. Commun. 2016, 7, 506-511

Fragment pharmacophore-based in silico screening: a powerful approach for efficient lead discovery

2015

BSI Summer School 2015

CD41 (Itga2b) identifies lymph node lymphatic endothelial cells activated by RANKL

SLAS 2015

The Prestwick Chemical Library®, a valuable tool for screening

WO 2015191799

Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof

WO 2015103489

Heteroatom containing deoxyuridine triphosphatase inhibitors

2014

EFMC-ISMC 2014

Structure-based discovery of novel NIK inhibitors

EFMC-ISMC 2014

Comparison of hit discovery approaches. Case study: NIK inhibitors

EFMC-ISMC 2014

Pharmacophore-based characterization of the Prestwick Chemical Library®

EFMC-ISMC 2014

High throughput behevioral sleep assay for larval zebrafish

SfN 2014

In vivo characterization of a novel highly potent GPR88 agonist

SLAS 2014

Screening for neuroprotective activity in a Drosophila model of Parkinson’s disease using a new Prestwick Drosophila library

WO 2014107622

Deoxyuridine triphosphatase inhibitors

WO 2014019023

Alpha7 nicotinic acetylcholine receptor modulators and uses thereof

US 20140088108

2-(3-Aminoaryl) amino-4-aryl-thiazoles and their use as c-Kit inhibitors

2013

Anal. Chem. 2013, 85(18), 8787-8795

Chemical library screening using a SPR-Based inhibition in solution assay: simulations and experimental validation

ANS 2013

BNC375, A novel positive allosteric modulator of the α7 nicotinic acetylcholine receptor, exhibits cognitive enhancement in rodent behavioural models

WO 2013174930

7-Oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease

WO 2013057251

Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease

WO 2013057253

Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

WO 2013174931

7-Oxo-4,7 -dihydro- pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease


2012

WO 2012103583

Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof

2011

Eur. J. Org. Chem. 2011, 32, 6409-6412

Expeditious route towards (+/-)-desethyleburnamonine, a precursor of (+/-) Vindeburnol

WO 2011051478

Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors

WO 2011073165

New phenylhydrazone derivatives and their use as pharmaceuticals


2010

WO 2010128163

Small molecule inhibitors of influenza A and B virus and respiratory syncytial virus replication

WO 2010128163

9-Substituted-β-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials

WO 2010128163

Styrylquinolines, their process of preparation and their therapeutic uses

WO 2010128163

Styrylquinolines, their process of preparation and their therapeutic uses

WO 2010128163

Styrylquinolines, their process of preparation and their therapeutic uses

US 20100113471

2-Aminoaryloxazole compounds as tyrosine kinase inhibitors

Before 2010


CROI 2009

A new quinoline family of HIV-1 integrase inhibitors acting on HIV-1 mutants selected by integrase strand transfer inhibitors

Rencontres Normandes en CBS 2009

New derivatives of 14,15-dihydro-20,21-dinoreburnamin-14-ol as potent antidepressants

WO 2009106967

Novel 7-substituted derivatives of 3-carboxy-oxadiazino-quinolones, preparation thereof and use thereof as anti-bacterial agents

WO 2008001016

Use of a carbonic anhydrase inhibitor for preparation of a drug for treating skeletal muscle degeneration

WO 2007125246

Use of a tricyclic compound for preparing a medicine for treating skeletal muscle degeneration


Before 2010


WO 2007107545

Cyclic-alkylaminederivatives as inhibitors of the interaction between Mdm2 and p53

WO 2007044796

Pyridazinone compounds as calcilytics

WO 2007045758

6-Heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof

WO 2006032631

Inhibitors of the interaction between Mdm2 and p53

WO 2006064375

Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases

WO 2006075012

Novel pyrrolodihydroisoquinolines

WO 2006089815

Novel Pyrrolodihydroisoquinolines as PDE10 inhibitors

WO 2006066070

Prodrug constructs of pyrimidone compounds as calcilytics

WO 2005040139

2-Aminoaryloxazole compounds as tyrosine kinase inhibitors

Before 2010


WO 2005073225

2-(3-Substituted-aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors

WO 2005003129

Pyrrolodihydroisoquinolines as PDE10 inhibitors

NWO 2005103047

Derivatives of 14,15-dihydro 20.21-dinoreburnamenin-14-ol, and applications thereof

WO 2005108398

6-Substituted pyridoindolone derivatives production and therapeutic use thereof

WO 2004014903

2-(3-Aminoaryl)amino-4-aryl-thiazoles and their use as c-Kit inhibitors

WO 2004016580

Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid

WO 2004041817

3-Phenyl substituted pyridoindolone, preparation and their therapeutic use thereof

US 7514454

Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders